Prevalence and importance of comorbidities in patients with heart failure

Current Heart Failure Reports

Volumn 9, Issue 4, 2012, Pages 354-362

  Triposkiadis, Filippos K ^a   Skoularigis, John ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

Author keywords

Comorbidities; Heart failure; Inflammation

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THYROID HORMONE; VASOACTIVE AGENT;

ANEMIA; ARTICLE; CARDIAC PATIENT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; COMORBIDITY; DEFIBRILLATOR; DEPRESSION; DIABETES MELLITUS; HEART FAILURE; HUMAN; HYPOTHYROIDISM; INFLAMMATION; KIDNEY DYSFUNCTION; LIVER DYSFUNCTION; LUNG DISEASE; MYOPATHY; OXYGEN THERAPY; PREVALENCE; PULMONARY HYPERTENSION; SLEEP DISORDERED BREATHING; THYROTOXICOSIS; VENTRICULAR ASSIST DEVICE;

ANEMIA; COMORBIDITY; DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; INFLAMMATION; KIDNEY DISEASES; LIVER DISEASES; LUNG DISEASES; MENTAL DISORDERS; MUSCULAR DISEASES; PREVALENCE; SLEEP APNEA SYNDROMES; THYROID DISEASES;

EID: 84872189040     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-012-0110-z     Document Type: Article

References (94)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: A report from the american heart association. Circulation. 2011;123:e18-e209.
2. Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. Heart. 2007;93:665-71.
3. Triposkiadis F, Starling RC, Boudoulas H, et al. The cardiorenal syndrome in heart failure: Cardiac? Renal? Syndrome? Hear Fail Rev. 2012;17:355-66. Interesting review article emphasizing the bidirectional associations between heart failure and coexisting morbidities and the lack of evidence regarding the presence of the cardiorenal syndrome.
4. Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012;59:998-1005. Important study which demonstrated a higher noncardiac comorbidity burden associated with higher non-heart failure (HF) hospitalizations in patients with HF and preserved (n02,843) vs. those with HF and depressed (n06,599) left ventricular ejection fraction during a 2-year follow-up.
5. Waxman AB. Pulmonary function test abnormalities in pulmonary vascular disease and chronic heart failure. Clinics in Chest Medicine. 2001;22:751-8. (Pubitemid 34020011)
6. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest. 2004;125:669-82.
7. Mettauer B, Lampert E, Charloux A, et al. Lung membrane diffusing capacity, heart failure, and heart transplantation. Am J Cardiol. 1999;83:62-7. (Pubitemid 29036649)
8. Szwejkowski BR, Elder DH, Shearer F, et al. Pulmonary hypertension predicts all-cause mortality in patients with heart failure: A retrospective cohort study. Eur J Hear Fail. 2012;14:162-7. Record linkage study in Tayside, Scotland utilizing the Tayside echocardiogram database (>50,000 echocardiograms).Patients were included in the analysis if they had left ventricular systolic dysfunction, right ventricular systolic pressure (RVSP) measurement, and a loop diuretic prescription (provided not more than 1 year prior to echocardiogram). Pulmonary hypertension predicted all-cause mortality in this heterogeneous group of patients with heart failure with each 5 mmHg rise in RVSP was associated with a 6% increased risk of death.
9. Chen Y, Guo H, Xu D, Xu X, et al. Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: Heart failure causes severe lung disease. Hypertension. 2012;59:1170-8.
10. Haddad F, Kudelko K, Mercier O, et al. Pulmonary hypertension associated with left heart disease: Characteristics, emerging concepts, and treatment strategies. Prog Cardiovasc Dis. 2011;54:154-67.
11. Hefke T, Zittermann A, Fuchs U, et al. Bosentan effects on hemodynamics and clinical outcome in heart failure patients with pulmonary hypertension awaiting cardiac transplantation. Thorac Cardiovasc Surg. 2012;60:26-34.
12. Hawkins NM, Petrie MC, Jhund PS, et al. Heart failure and chronic obstructive pulmonary disease: Diagnostic pitfalls and epidemiology. Eur J Hear Fail. 2009;11:130-9.
13. Kwon BJ, Kim DB, Jang SW, et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease. Eur J Hear Fail. 2010;12:1339-44. This study demonstrated in 184 patients with coexistent heart failure (HF) and chronic obstructive pulmonary disease that cardiovascular and pulmonary event-free survival of HF with preserved left ventricular ejection fraction (LVEF) is similar to that of HF with depressed LVEF over 3 years follow-up.
14. Zeng Q, Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. Journal of Thoracic Disease. 2012;4:310-5.
15. White DP. Pathogenesis of obstructive and central sleep apnoea. Am J Respir Crit Care Med. 2005;172:1363-70.
16. Kasai T, Bradley TD. Obstructive sleep apnoea and heart failure: Pathophysiologic and therapeutic implications. J Am Coll Cardiol. 2011;57:119-27.
17. Bradley TD, Floras JS. Sleep apnoea and heart failure: Part ii: Central sleep apnoea. Circulation. 2003;107:1822-6. (Pubitemid 36418366)
18. Khayat R, Abraham W, Patt B, et al. Central sleep apnoea is a predictor of cardiac readmission in hospitalized patients with systolic heart failure. J Card Fail. 2012;18:534-40. Prospective observational cohort study of hospitalized patients with systolic heart failure (n0784) evaluating the impact of sleep disordered breathing on cardiac readmissions. It demonstrated that central sleep apnoea (CSA) is an independent risk factor for 6 months' cardiac readmissions and that effect size of CSA exceeds that of all known predictors of heart failure readmissions.
19. Bitter T, Westerheide N, Prinz C, et al. Cheyne-stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverterdefibrillator therapies in patients with congestive heart failure. Eur Hear J. 2011;32:61-74. Large-scale long-Term study including 472 patients with congestive heart failure after implantation of a cardiac resynchronization device with cardioverter- defibrillator. It demonstrated an association between obstructive sleep apnoea and/or central sleep apnoea and risk for malignant cardiac arrhythmia.
20. Momomura S. Treatment of Cheyne-Stokes respiration-central sleep apnoea in patients with heart failure. J Cardiol. 2012;59:110-6.
21. Sharma BK, Bakker JP, McSharry DG, et al.: Adaptive servoventilation for treatment of sleep-disordered breathing in heart failure: A systematic review and meta-Analysis. Chest. 2012 Jun 21. [Epub ahead of print]. A systematic search including 14 studies (n0538) which demonstrated that adaptive servo-ventilation (ASV) in adult patients with heart failure and sleep disordered breathing reduces the apnoea/hypopnoea index and improves cardiac function and exercise capacity, providing a rationale for large-scale randomized controlled trials to assess the clinical impact of ASV on hard outcomes in these patients.
22. Udani SM, Koyner JL. The effects of heart failure on renal function. Cardiol Clin. 2010;28:453-65.
23. El Nahas M. Cardio-Kidney-Damage: a unifying concept. Kidney Int. 2010;78:14-8. A rational theory which claims that the high prevalence of heart failure and chronic kidney disease in the elderly population is likely to reflect the underlying high prevalence of overt and subclinical atherosclerosis and cardiovascular disease.
24. Zoccali C, Goldsmith D, Agarwal R, et al. The complexity of the cardio-renal link: taxonomy, syndromes, and diseases. Kidney International Supplements. 2011;1:2-5. Review article emphasizing the lack of evidence regarding the presence of the cardiorenal syndrome.
25. Smith GL, Lichtman JH, Bracken MB, et al. Renal impairment and outcomes in heart failure: Systematic review and meta-Analysis. J Am Coll Cardiol. 2006;47:1987-96.
26. Gardner RS, Chong KS, O'Meara E, et al. Renal dysfunction, as measured by the modification of diet in renal disease equations, and outcome in patients with advanced heart failure. Eur Hear J. 2007;28:3027-33.
27. Giamouzis G, Butler J, Triposkiadis F. Renal function in advanced heart failure. Congestive Heart Failure. 2011;17:180-8.
28. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized heart failure patients: Results of the dopamine in acute decompensated heart failure (DAD-HF) trial. J Card Fail. 2010;16:922-30. Small study in patients with acutely decompensated heart failure which demostrated that the combination of low-dose furosemide and low-dose dopamine (5 μgkg-1min-1 continuous infusion for 8 hours) is equally effective as high-dose furosemide but associated with improved renal function profile and potassium homeostasis.
29. Jokinen JJ, Tikkanen J, Kukkonen S, et al. Natural course and risk factors for impaired renal function during the first year after heart transplantation. Journal of Heart and Lung Transplantation. 2010;29:633-40.
30. Odim J, Wheat J, Laks H, et al. Peri-operative renal function and outcome after orthotopic heart transplantation. Journal of Heart and Lung Transplantation. 2006;25:162-6. (Pubitemid 43156366)
31. Benck U, Hoeger S, Brinkkoetter PT, et al. Effects of donor pretreatment with dopamine on survival after heart transplantation: A cohort study of heart transplant recipients nested in a randomized controlled multicenter trial. J Am Coll Cardiol. 2011;58:1768-77.
32. Poelzl G, Ess M, Mussner-Seeber C, et al. Liver dysfunction in chronic heart failure: Prevalence, characteristics and prognostic significance. Eur J Clin Investig. 2012;42:153-63.
33. Giallourakis CC, Rosenberg PM, Friedman LS. The liver in heart failure. Clinics in Liver Dsease. 2002;6:947-67. viii-ix.
34. Moller S, Dumcke CW, Krag A. The heart and the liver. Expert Review of Gastroenterology & Hepatology. 2009;3:51-64.
35. Allen LA, Felker GM, Pocock S, et al. Liver function abnormalities and outcome in patients with chronic heart failure: Data from the candesartan in heart failure: Assessment of reduction in mortality and morbidity (charm) program. Eur J Hear Fail. 2009;11:170-7. Evaluation of prevalence and importance of liver function test (LFT) abnormalities in a large (n02679) cohort of heart failure patients. Elevated total bilirubin was the strongest LFT predictor of adverse outcome for both the composite outcome of cardiovascular death or heart failure hospitalization and allcause mortality.
36. Ambrosy AP, Vaduganathan M, Huffman MD, et al. Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: An analysis of the EVEREST trial. Eur J Hear Fail. 2012;14:302-11. Post-hoc analysis of the placebo group of the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan) trial including patients hospitalized for systolic heart failure which demonstrated that baseline and in-hospital changes in serum albumin and total billirubin provide additional prognostic value.
37. Anand IS. Pathophysiology of anaemia in heart failure. Heart Failure Clinics. 2010;6:279-88.
38. Young JB, Abraham WT, Albert NM, et al. Relation of low hemoglobin and anaemia to morbidity and mortality in patients hospitalized with heart failure (insight from the OPTIMIZE-HF registry). Am J Cardiol. 2008;101:223-30.
39. Groenveld HF, Januzzi JL, Damman K, et al. Anaemia and mortality in heart failure patients: a systematic review and metaanalysis. J Am Coll Cardiol. 2008;52:818-27.
40. Adams Jr KF, Patterson JH, Oren RM, et al. Prospective assessment of the occurrence of anaemia in patients with heart failure: Results from the study of anaemia in a heart failure population (STAMINA-HFP) registry. Am Hear J. 2009;157:926-32.
41. Tang YD, Katz SD. Anaemia in chronic heart failure: Prevalence, etiology, clinical correlates, and treatment options. Circulation. 2006;113:2454-61.
42. Horwich TB, Fonarow GC, Hamilton MA, et al. Anaemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-6. (Pubitemid 34595288)
43. Le Jemtel TH, Arain S. Mediators of anaemia in chronic heart failure. Heart Failure Clinics. 2010;6:289-93.
44. Giamouzis G, Kalogeropoulos A, Georgiopoulou V, et al. Hospitalization epidemic in patients with heart failure: Risk factors, risk prediction, knowledge gaps, and future directions. J Card Fail. 2011;17:54-75.
45. TangWH, TongW, Jain A, et al. Evaluation and long-Term prognosis of new-onset, transient, and persistent anaemia in ambulatory patients with chronic heart failure. J Am Coll Cardiol. 2008;51:569-76.
46. Alexandrakis MG, Tsirakis G. Anaemia in heart failure patients. ISRN Hematology. 2012;2012:246915. Epub 2012 Mar 25.
47. Olivares EL, Carvalho DP. Thyroid hormone metabolism in heart failure: Iodothyronine deiodinases in focus. Current Opinion in Endocrinology, Diabetes, and Obesity. 2010;17:414-7.
48. Ladenson PW, Sherman SI, Baughman KL, et al. Reversible alterations in myocardial gene expression in a young man with dilated cardiomyopathy and hypothyroidism. Proc Natl Acad Sci U S A. 1992;89:5251-5.
49. Klein I, Danzi S. Thyroid hormone treatment to mend a broken heart. J Clin Endocrinol Metab. 2008;93:1172-4. (Pubitemid 351519704)
50. Gerdes AM, Iervasi G. Thyroid replacement therapy and heart failure. Circulation. 2010;122:385-93.
51. Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nature reviews Endocrinology. 2010;6:34-41. Review paper on the pathophyiology identification, and management of amidarone-induced thyroid abnormalities in patients with heart failure.
52. From AM, Leibson CL, Bursi F, et al. Diabetes in heart failure: Prevalence and impact on outcome in the population. Am J Med. 2006;119:591-9. (Pubitemid 44041273)
53. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: A report from the acute decompensated heart failure national registry (ADHERE) database. J Am Coll Cardiol. 2006;47:76-84.
54. MacDonald MR, Petrie MC, Varyani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the candesartan in heart failure: Assessment of reduction in mortality and morbidity (CHARM) programme. Eur Hear J. 2008;29:1377-85.
55. Kamalesh M, Cleophas TJ. Heart failure due to systolic dysfunction and mortality in diabetes: Pooled analysis of 39,505 subjects. J Card Fail. 2009;15:305-9.
56. Al Zadjali MA, Godfrey V, Khan F, et al. Insulin resistance is highly prevalent and is associated with reduced exercise tolerance in nondiabetic patients with heart failure. J Am Coll Cardiol. 2009;53:747-53. This study demonstrated in a cohort of 129 consecutive nondiabetic heart failure patients that 61% suffer from insulin resistance (IR), IR increases significantly with worsening New York Heart Association functional class, and that the presence of IR is associated with a significantly lower exercise capacity and peak oxygen consumption.
57. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation. 2007;116:434-48.
58. Eurich DT, McAlister FA, Blackburn DF, et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: Systematic review. British Medical Journal. 2007;335(7618):497. Epub 2007 Aug 30.
59. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2004;27:256-63.
60. Georgiadou P, Adamopoulos S. Skeletal muscle abnormalities in chronic heart failure. Current Heart Failure Reports. 2012;9:128-32.
61. Strassburg S, Springer J, Anker SD. Muscle wasting in cardiac cachexia. Int J Biochem Cell Biol. 2005;37:1938-47.
62. von Haehling S, Stepney R, Anker SD. Advances in understanding and treating cardiac cachexia: Highlights from the 5th cachexia conference. Int J Cardiol. 2010;144:347-9.
63. Duscha BD, Schulze PC, Robbins JL, Forman DE. Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Hear Fail Rev. 2008;13:21-37.
64. Cicoira M, Zanolla L, Franceschini L, et al. Skeletal muscle mass independently predicts peak oxygen consumption and ventilatory response during exercise in noncachectic patients with chronic heart failure. J Am Coll Cardiol. 2001;37:2080-5. (Pubitemid 32548001)
65. Coats AJ. The "muscle hypothesis" of chronic heart failure. J Mol Cell Cardiol. 1996;28:2255-62.
66. Rehn TA, Munkvik M, Lunde PK, et al. Intrinsic skeletal muscle alterations in chronic heart failure patients: A disease-specific myopathy or a result of deconditioning? Hear Fail Rev. 2012;17:421-36. Critical review of the evidence for skeletal muscle alterations in CHF, the underlying mechanisms of such alterations and how skeletal muscle responds to training in this patient group.
67. Rutledge T, Reis VA, Linke SE, et al. Depression in heart failure a meta-Analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48:1527-37.
68. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55:580-92.
69. Jiang W, Alexander J, Christopher E, et al. Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med. 2001;161:1849-56.
70. Albert NM, Fonarow GC, Abraham WT, et al. Depression and clinical outcomes in heart failure: An OPTIMIZE-HF analysis. Am J Med. 2009;122:366-73.
71. Freedland KE, Carney RM, Rich MW. Effect of depression on prognosis in heart failure. Heart Failure Clinics. 2011;7:11-21.
72. O'Connor CM, Jiang W, Kuchibhatla M, et al. Safety and efficacy of sertraline for depression in patients with heart failure: Results of the SADHART-CHF (sertraline against depression and heart disease in chronic heart failure) trial. J Am Coll Cardiol. 2010;56:692-9. The SADHART-CHF trial was a randomized, double-blind, placebocontrolled trial of sertraline 50 to 200 mg/day (n0234) versus matching placebo (n0235) for 12 weeks in patients with systolic heart failure and clinical depression. Although, sertraline was safe, it did not provide greater reduction in depression or improved cardiovascular status among patients with HF and depression.
73. Dardiotis E, Giamouzis G, Mastrogiannis D, et al. Cognitive impairment in heart failure. Cardiol Res Pract. 2012;2012:595821. Epub 2012 Jun 6.
74. Vogels RL, Oosterman JM, van Harten B, et al. Profile of cognitive impairment in chronic heart failure. J Am Geriatr Soc. 2007;55:1764-70.
75. Trojano L. Antonelli Incalzi R, Acanfora D, et al.: Cognitive impairment: A key feature of congestive heart failure in the elderly. J Neurol. 2003;250:1456-63.
76. Zuccala G, Onder G, Marzetti E, et al. Use of angiotensin-converting enzyme inhibitors and variations in cognitive performance among patients with heart failure. Eur Hear J. 2005;26:226-33.
77. Kalogeropoulos AP, Georgiopoulou VV, Butler J. From risk factors to structural heart disease: The role of inflammation. Heart Failure Clinics. 2012;8:113-23.
78. Silverstein DM. Inflammation in chronic kidney disease: Role in the progression of renal and cardiovascular disease. Pediatr Nephrol. 2009;24:1445-52.
79. Cottone S, Lorito MC, Riccobene R, et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. Journal of Nephrology. 2008;21:175-9.
80. McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnoea: Overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med. 2009;180:692-700.
81. Ryan S, Taylor CT, McNicholas WT. Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnoea syndrome. Circulation. 2005;112:2660-7. (Pubitemid 41532603)
82. Im SS, Osborne TF. Liver x receptors in atherosclerosis and inflammation. Circ Res. 2011;108:996-1001.
83. Iredale JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ. The Journal of Cclinical Investigation. 2007;117:539-48.
84. Maher JJ, McGuire RF. Extracellular matrix gene expression increases preferentially in rat lipocytes and sinusoidal endothelial cells during hepatic fibrosis in vivo. J Clin Invest. 1990;86:1641-8. (Pubitemid 20372615)
85. Opasich C, Cazzola M, Scelsi L, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. Eur Hear J. 2005;26:2232-7. (Pubitemid 41541385)
86. Kleijn L, Belonje AM, Voors AA, et al.: Inflammation and anaemia in a broad spectrum of patients with heart failure. Heart. 2012 Jun 22. [Epub ahead of print]. Multicentre randomised clinical trial including patients admitted for heart failure (n0326), which demonstrated that anaemia (Hb <13 g/dl (men) and <12 g/dl (women)) was present in 40% (130/326) of the study population and that that the levels of IL-6, hsCRP and sTNFR-1 were significantly higher in anaemic than in non-Anaemic patients emphasizing the association between anaemia and inflammation.
87. Garcia C, Feve B, Ferre P, et al. Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes & Metabolism. 2010;36:327-38.
88. Ehses JA, Ellingsgaard H, Boni-Schnetzler M, DonathMY. Pancreatic islet inflammation in type 2 diabetes: From alpha and beta cell compensation to dysfunction. Arch Physiol Biochem. 2009;115:240-7.
89. Hambrecht R, Adams V, Gielen S, et al. Exercise intolerance in patients with chronic heart failure and increased expression of inducible nitric oxide synthase in the skeletal muscle. J Am Coll Cardiol. 1999;33:174-9. (Pubitemid 29064089)
90. Adams V, Jiang H, Yu J, et al. Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J Am Coll Cardiol. 1999;33:959-65.
91. Bartalena L, Bogazzi F, Brogioni S, et al. Role of cytokines in the pathogenesis of the euthyroid sick syndrome. European Journal of Endocrinology /European Federation of Endocrine Societies. 1998;138:603-14.
92. Reichlin S. Neuroendocrine-immune interactions. N Engl J Med. 1993;329:1246-53.
93. Krishnadas R, Cavanagh J. Depression: An inflammatory illness? J Neurol Neurosurg Psychiatry. 2012;83:495-502.
94. Gorelick PB. Role of inflammation in cognitive impairment: Results of observational epidemiological studies and clinical trials. Ann N Y Acad Sci. 2010;1207:155-62. Review of the observations that have led to the establishment of an association of systemic and brain inflammatory markers on cognitive impairment and dementia.